Expression of EBI2 in lymphoma patients. (A) qPCR analysis of EBI2 transcript levels in CD10⁺ and CD10⁻ cancers relative to the mean expression level of the healthy control samples. The cDNA samples in the array had been prenormalized to β-actin. The results are mean ± SEM of data from 6 to 14 samples. *P < .05 and ***P < .001 by Student t test. (B) Expression data on EBI2 expression in CLL patients compared with healthy controls. Expression data from Gene Expression Omnibus (GEO) profiles reprinted from Gutierrez et al,⁴⁵  Gutiérrez et al⁴⁶  with permission, and Fält et al⁴⁷  with permission. (C) qPCR analysis of mEBI2 transcript levels in spleen cells from young (12-15 weeks) and older, lymphoma IgH-hEBI2 mice relative to the expression of the control gene GAPDH. The results are mean ± SEM of data from 5 to 6 mice. **P < .01 by the nonparametric Mann-Whitney test. (D) qPCR analysis of hEBI2 transcript levels in spleen cells from young (12-15 weeks) and older, lymphoma IgH-hEBI2 mice relative to the expression of the control gene GAPDH. The results are mean ± SEM of data from 5 to 6 mice. ***P < .001 by the nonparametric Mann-Whitney test. (E-G) The B1a cell subsets in spleen (E), blood (F), and peritoneal cavity (G) samples from 4-day-old WT and IgH-hEBI2 mice were analyzed by FACS. The number of B1 B cells is given as percentage of total lymphocytes in the samples. The results are mean ± SEM of data from 3 to 7 mice. **P < .01 and ***P < .001 by Student t test.